Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Kanda, Mitsuro ^a   Nomoto, Shuji ^a   Oya, Hisaharu ^a   Shimizu, Dai ^a   Takami, Hideki ^a   Hibino, Soki ^a   Hashimoto, Ryoji ^a   Kobayashi, Daisuke ^a   Tanaka, Chie ^a   Yamada, Suguru ^a   Fujii, Tsutomu ^a   Nakayama, Goro ^a   Sugimoto, Hiroyuki ^a   Koike, Masahiko ^a   Fujiwara, Michitaka ^a   Kodera, Yasuhiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Dihydropyrimidinase like 3; Expression; Gastric cancer; Prognosis

Indexed keywords

CELL ADHESION MOLECULE; DIHYDROPYRIMIDINASE LIKE 3; EZRIN; FOCAL ADHESION KINASE; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; DPYSL3 PROTEIN, HUMAN; MUSCLE PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; DISTANT METASTASIS; FEMALE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STOMACH CANCER; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; STOMACH NEOPLASMS; TIME; TUMOR CELL LINE; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE PROTEINS; NEOPLASM METASTASIS; NEOPLASM STAGING; PHENOTYPE; RNA, MESSENGER; STOMACH NEOPLASMS; TIME FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 84906928192     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-014-0066-9     Document Type: Article

References (33)

1. Global cancer statistics. A Jemal, F Bray, MM Center, J Ferlay, E Ward, D Forman, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. T Ivanova, H Zouridis, Y Wu, LL Cheng, IB Tan, V Gopalakrishnan, CH Ooi, J Lee, L Qin, J Wu, M Lee, SY Rha, D Huang, N Liem, KG Yeoh, WP Yong, BT Teh, P Tan, Gut 2013 62 22 33 10.1136/gutjnl-2011-301113 22535375
3. Management of gastric cancer in Asia: resource-stratified guidelines. L Shen, YS Shan, HM Hu, TJ Price, B Sirohi, KH Yeh, YH Yang, T Sano, HK Yang, X Zhang, SR Park, M Fujii, YK Kang, LT Chen, Lancet Oncol 2013 14 535 547 10.1016/S1470-2045(13)70436-4 24176572
4. Gastric cancer. HH Hartgrink, EP Jansen, NC van Grieken, CJ van de Velde, Lancet 2009 374 477 490 10.1016/S0140-6736(09)60617-6 19625077
5. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. AD Wagner, W Grothe, J Haerting, G Kleber, A Grothey, WE Fleig, J Clin Oncol 2006 24 2903 2909 10.1200/JCO.2005.05.0245 16782930
6. Metastasis suppressors alter the signal transduction of cancer cells. PS Steeg, Nat Rev Cancer 2003 3 55 63 10.1038/nrc967 12509767
7. Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. M Kanda, S Nomoto, Y Okamura, M Hayashi, M Hishida, T Fujii, Y Nishikawa, H Sugimoto, S Takeda, A Nakao, Mol Carcinog 2011 50 571 579 10.1002/mc.20735 21268132
8. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. CA Gonzalez, A Agudo, Int J Cancer 2012 130 745 753 10.1002/ijc.26430 21918974
9. Genomic dysregulation in gastric tumors. YY Janjigian, DP Kelsen, J Surg Oncol 2013 107 237 242 10.1002/jso.23263 23042588
10. Molecular pathology of gastric carcinoma. BG Jang, WH Kim, Pathobiology 2011 78 302 310 10.1159/000321703 22104201
11. Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Y Goshima, F Nakamura, P Strittmatter, SM Strittmatter, Nature 1995 376 509 514 10.1038/376509a0 7637782
12. Structure and promoter analysis of the human unc-33-like phosphoprotein gene. E-box required for maximal expression in neuroblastoma and myoblasts. T Matsuo, JK Stauffer, RL Walker, P Meltzer, CJ Thiele, J Biol Chem 2000 275 16560 16568 10.1074/jbc.M001312200 10748015
13. http://biogps.org/ BioGPS.
14. Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer. X Gao, J Pang, LY Li, WP Liu, JM Di, QP Sun, YQ Fang, XP Liu, XY Pu, D He, MT Li, ZL Su, BY Li, Oncogene 2010 29 4555 4566 10.1038/onc.2010.213 20543870
15. Quantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinoma-associated molecule that regulates cell adhesion and migration by stabilization of focal adhesion complex. T Kawahara, N Hotta, Y Ozawa, S Kato, K Kano, Y Yokoyama, M Nagino, T Takahashi, K Yanagisawa, PLoS One 2013 8 79654 10.1371/journal.pone.0079654 24339867
16. Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. M Kanda, S Nomoto, Y Nishikawa, H Sugimoto, N Kanazumi, S Takeda, A Nakao, J Surg Oncol 2008 98 190 196 10.1002/jso.21095 18537151
17. LH Sobin, MK Gospodarowicz, C Wittekind, International Union Against Cancer, TNM Classification of Malignant Tumors Wiley-Blackwell, New York 2009
18. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. S Sakuramoto, M Sasako, T Yamaguchi, T Kinoshita, M Fujii, A Nashimoto, H Furukawa, T Nakajima, Y Ohashi, H Imamura, M Higashino, Y Yamamura, A Kurita, K Arai, N Engl J Med 2007 357 1810 1820 10.1056/NEJMoa072252 17978289
19. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. M Sasako, S Sakuramoto, H Katai, T Kinoshita, H Furukawa, T Yamaguchi, A Nashimoto, M Fujii, T Nakajima, Y Ohashi, J Clin Oncol 2011 29 4387 4393 10.1200/JCO.2011.36.5908 22010012
20. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. M Kanda, S Nomoto, Y Okamura, Y Nishikawa, H Sugimoto, N Kanazumi, S Takeda, A Nakao, Int J Oncol 2009 35 477 483 10.3892/ijo-00000448 19639168
21. Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. Y Inokawa, S Nomoto, M Hishida, M Hayashi, M Kanda, Y Nishikawa, S Takeda, H Sugimoto, T Fujii, S Yamada, Y Kodera, J Exp Clin Cancer Res 2013 32 65 24034596
22. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma. D Shimizu, M Kanda, S Nomoto, H Oya, H Takami, S Hibino, M Suenaga, Y Inokawa, M Hishida, N Takano, Y Nishikawa, S Yamada, T Fujii, G Nakayama, H Sugimoto, M Koike, M Fujiwara, Y Kodera, Oncol Rep 2014 31 1305 1313 24366000
23. Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. M Kanda, S Nomoto, H Oya, H Takami, S Hibino, M Hishida, M Suenaga, S Yamada, Y Inokawa, Y Nishikawa, M Asai, T Fujii, H Sugimoto, Y Kodera, Int J Oncol 2014 44 44 52 24189587
24. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). A Loupy, GS Hill, C Suberbielle, D Charron, D Anglicheau, J Zuber, MO Timsit, JP Duong, P Bruneval, D Vernerey, JP Empana, X Jouven, D Nochy, CH Legendre, Am J Transplant 2011 11 56 65 10.1111/j.1600-6143.2010.03364.x 21199348
25. Clinical significance of expression and epigenetic profiling of TUSC1 in gastric cancer. M Kanda, D Shimizu, S Nomoto, S Hibino, H Oya, H Takami, D Kobayashi, S Yamada, Y Inokawa, C Tanaka, T Fujii, H Sugimoto, M Koike, M Fujiwara, Y Kodera, J Surg Oncol 2014 110 136 144 24700496
26. Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus. S Hibino, M Kanda, H Oya, H Takami, D Shimizu, S Nomoto, M Hishida, Y Niwa, M Koike, S Yamada, Y Nishikawa, M Asai, G Nakayama, T Fujii, H Sugimoto, M Fujiwara, Y Kodera, Oncol Rep 2014 31 693 700 24317529
27. The FERM domain: organizing the structure and function of FAK. MC Frame, H Patel, B Serrels, D Lietha, MJ Eck, Nat Rev Mol Cell Biol 2010 11 802 814 10.1038/nrm2996 20966971
28. Organizing the cell cortex: the role of ERM proteins. RG Fehon, AI McClatchey, A Bretscher, Nat Rev Mol Cell Biol 2010 11 276 287 10.1038/nrm2866 20308985
29. Src-dependent ezrin phosphorylation in adhesion-mediated signaling. J Srivastava, BE Elliott, D Louvard, M Arpin, Mol Biol Cell 2005 16 1481 1490 10.1091/mbc.E04-08-0721 15647376
30. Characteristics and clinical outcome of proximal-third gastric cancer. T Sakaguchi, A Watanabe, H Sawada, Y Yamada, M Tatsumi, H Fujimoto, K Emoto, H Nakano, J Am Coll Surg 1998 187 352 357 10.1016/S1072-7515(98)00191-4 9783780
31. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. P Vogiatzi, C Vindigni, F Roviello, A Renieri, A Giordano, J Cell Physiol 2007 211 287 295 10.1002/jcp.20982 17238139
32. Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. M Kanda, D Shimizu, S Nomoto, H Takami, S Hibino, H Oya, R Hashimoto, M Suenaga, Y Inokawa, D Kobayashi, C Tanaka, S Yamada, T Fujii, G Nakayama, H Sugimoto, M Koike, M Fujiwara, Y Kodera, Gastric Cancer 2014 Epub ahead of print, PubMed PMID: 24695972
33. L1 and epithelial cell adhesion molecules associated with gastric cancer progression and prognosis in examination of specimens from 601 patients. YY Wang, L Li, ZS Zhao, YX Wang, ZY Ye, HQ Tao, J Exp Clin Cancer Res 2013 32 66 24422715